Faculty Opinions recommendation of The S52F FOXF1 mutation inhibits STAT3 signaling and causes alveolar capillary dysplasia.

Author(s):  
Lawrence Nogee
2019 ◽  
Vol 200 (8) ◽  
pp. 1045-1056 ◽  
Author(s):  
Arun Pradhan ◽  
Andrew Dunn ◽  
Vladimir Ustiyan ◽  
Craig Bolte ◽  
Guolun Wang ◽  
...  

1997 ◽  
Vol 17 (6) ◽  
pp. 959-975 ◽  
Author(s):  
Sibylle Haraida ◽  
Hannelore Lochbuhler ◽  
A. Heger ◽  
A. Nerlich ◽  
J. Diebold ◽  
...  

Author(s):  
Chloé Puisney‐Dakhli ◽  
Francesca Gubana ◽  
François Petit ◽  
Hanane Bouchghoul ◽  
Valérie Gautier ◽  
...  

2018 ◽  
Vol 46 (1) ◽  
pp. 101-101
Author(s):  
Katharine Robb ◽  
Sook-kyung Kwon ◽  
Veerajalandhar Allareddy ◽  
Aditya Badheka

2018 ◽  
Vol 8 (3) ◽  
pp. 204589401879514 ◽  
Author(s):  
Evelien Slot ◽  
Gabriëla Edel ◽  
Ernest Cutz ◽  
Arno van Heijst ◽  
Martin Post ◽  
...  

Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD/MPV) is a rare and lethal disorder mainly involving the vascular development of the lungs. Since its first description, significant achievements in research have led to a better understanding of the underlying molecular mechanism of ACD/MPV and genetic studies have identified associations with genomic alterations in the locus of the transcription factor FOXF1. This in turn has increased the awareness among clinicians resulting in over 200 cases reported so far, including genotyping of patients in most recent reports. Collectively, this promoted a better stratification of the patient group, leading to new perspectives in research on the pathogenesis. Here, we provide an overview of the clinical aspects of ACD/MPV, including guidance for clinicians, and review the ongoing research into the complex molecular mechanism causing this severe lung disorder.


Sign in / Sign up

Export Citation Format

Share Document